AbbVie (ABBV) Change in Accured Expenses (2012 - 2026)

AbbVie (ABBV) has 15 years of Change in Accured Expenses data on file, last reported at -$1.6 billion in Q1 2026.

• Quarterly Change in Accured Expenses fell 129.02% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.0 million (up 106.02% YoY) and the FY2025 annual result came in at $951.0 million, up 437.29% from the prior year.
• Change in Accured Expenses eased to -$1.6 billion in Q1 2026 per ABBV's latest filing, from -$598.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.5 billion in Q3 2023 and bottomed at -$1.7 billion in Q2 2024.
• The 5-year median for Change in Accured Expenses is $267.0 million (2024), against an average of $302.5 million.
• The widest annual swing landed in 2022, when Change in Accured Expenses tumbled 363.89%; it then jumped 928.42% in 2023.
• Tracing ABBV's Change in Accured Expenses over 5 years: stood at $1.3 billion in 2022, then sank by 85.99% to $179.0 million in 2023, then jumped by 596.65% to $1.2 billion in 2024, then tumbled by 147.96% to -$598.0 million in 2025, then tumbled by 166.56% to -$1.6 billion in 2026.
• Per Business Quant, the three latest ABBV Change in Accured Expenses figures stand at -$1.6 billion (Q1 2026), -$598.0 million (Q4 2025), and $1.7 billion (Q3 2025).

Peer Comparison